Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation
Authors' conclusion
Our results support long-term OAC monotherapy beyond 1 year after PCI in patients with atrial fibrillation and suggest that DOAC monotherapy is as safe and effective as VKA monotherapy.
Study context
- Population
- Patients with atrial fibrillation (AF) undergoing first-time percutaneous coronary intervention (PCI), 2003–2017, Western Denmark Heart Registry; follow-up from 15 months after PCI for up to 4 years1,275 in direct oral anticoagulant (DOAC) vs vitamin K antagonist (VKA) analysis
- Participants
- 3,331 patients
- Exposure
- OAC monotherapy vs dual therapy (anticoagulant + antiplatelet) beyond 1 year after PCI; DOAC vs VKA monotherapy
- Outcome
- Hospitalization for bleeding and MACE
- Follow-up
- Up to 4 years from 15 months after PCI
Methodological detailsWestern Denmark Heart Registry, weighted Cox regression
- Western Denmark Heart Registry
- Weighted Cox regression
Main finding
As reported in the abstract
HRw
- Monotherapy vs Dual therapy · hospitalization for bleeding
- 0.90 (95% CI 0.75–1.09)
- Monotherapy vs Dual therapy · MACE
- 1.04 (95% CI 0.90–1.19)
- DOAC vs VKA · hospitalization for bleeding
- 1.27 (95% CI 0.84–1.92)
- DOAC vs VKA · MACE
- 1.15 (95% CI 0.87–1.50)
Observational data: associations, not effects.
Original publication
Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. Published 21 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →